FALCON Trademark

Trademark Overview

On Wednesday, January 5, 2022, a trademark application was filed for FALCON with the United States Patent and Trademark Office. The USPTO has given the FALCON trademark a serial number of 97203854. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Friday, December 13, 2024. This trademark is owned by DTx Pharma, Inc.. The FALCON trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical research and development of fatty acid-conjugated oligonucleotide compounds; scientific research and product development in the field of fatty acid-conjugated oligonucleotide compounds and drug discovery for peripheral nervous system, muscular, and central nervous system disorders; Pharmaceutical research and development of fatty acid-based drug delivery platforms for use in therapeutic discovery and development for peripheral nervous system, muscular, and central nervous system disorders; Pharmaceutical research and development of fatty acid-based drug delivery platforms for use in the treatment of genetic diseases, none of the foregoing related to otorhinolaryngology or otorhinolaryngological pharmaceuticals

General Information

Serial Number97203854
Word MarkFALCON
Filing DateWednesday, January 5, 2022
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateFriday, December 13, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical research and development of fatty acid-conjugated oligonucleotide compounds; scientific research and product development in the field of fatty acid-conjugated oligonucleotide compounds and drug discovery for peripheral nervous system, muscular, and central nervous system disorders; Pharmaceutical research and development of fatty acid-based drug delivery platforms for use in therapeutic discovery and development for peripheral nervous system, muscular, and central nervous system disorders; Pharmaceutical research and development of fatty acid-based drug delivery platforms for use in the treatment of genetic diseases, none of the foregoing related to otorhinolaryngology or otorhinolaryngological pharmaceuticals

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, January 10, 2022
Primary Code042
First Use Anywhere DateMonday, October 5, 2020
First Use In Commerce DateMonday, October 5, 2020

Trademark Owner History

Party NameDTx Pharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events

Event DateEvent Description
Saturday, January 8, 2022NEW APPLICATION ENTERED
Monday, January 10, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 11, 2022ASSIGNED TO EXAMINER
Tuesday, October 18, 2022NON-FINAL ACTION WRITTEN
Tuesday, October 18, 2022NON-FINAL ACTION E-MAILED
Tuesday, October 18, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 18, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 18, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 19, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, May 22, 2023SUSPENSION LETTER WRITTEN
Monday, May 22, 2023LETTER OF SUSPENSION E-MAILED
Monday, May 22, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, December 12, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, December 12, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, December 12, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, December 12, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, January 8, 2024REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, March 21, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, August 27, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 27, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 27, 2024ASSIGNED TO LIE
Friday, October 4, 2024SUSPENSION LETTER WRITTEN
Friday, October 4, 2024LETTER OF SUSPENSION E-MAILED
Friday, October 4, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, December 10, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, December 10, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, December 10, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, December 10, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, December 10, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, December 12, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, December 13, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 13, 2024TEAS/EMAIL CORRESPONDENCE ENTERED

Related Keywords

falcon development nervous acid system research fatty drug pharmaceutical muscular disorders